Search clinical trials for: Laquinimod 0.6

Total 4361 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Relapsing Remitting Multiple Sclerosis
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

Multiple Sclerosis

United States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod (LEGATO-HD)

Huntington's Disease

United States, Canada, Czechia, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Laquinimod Phase IIa Study in Active Crohn's Disease

Crohn's Disease

Belgium, France, Israel, Italy, Netherlands, Poland, South Africa, Spain, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis

Lupus Arthritis

United States, Canada
Active Biotech AB

Completed

Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

Denmark, Sweden
Teva Pharmaceutical Industries, Ltd.

Terminated

An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease

Relapsing Remitting Multiple Sclerosis

Czechia, Germany, Hungary, Israel, Italy, Poland, Russian Federation, Spain, United Kingdom
Active Biotech AB

Completed

An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis Patients Treated With ABR-215757 (Paquinimod)

Systemic Sclerosis

Germany, Sweden, Switzerland
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)

Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Relapsing Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
H. Lundbeck A/S

Completed

An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

Parkinson Disease

United States
Faes Farma, S.A.
ORA, Inc.

Completed

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

Allergic Conjunctivitis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
University of Texas Southwestern Medical Center
US Department of Veterans Affairs

Completed

Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer

Rectal Cancer

United States
Sichuan Haisco Pharmaceutical Group Co., Ltd
The First Hospital of Jilin University

Completed

Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Healthy Elderly Subjects

Healthy Elderly Subjects

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Sunstar Americas

Completed

GUIDOR® Growth Factor Enhanced Bone Graft Substitute for the Treatment of Periodontal Defects 6-months Post-Surgery

Periodontal Diseases | Alveolar Bone Loss

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together

Pharmacokinetics | Pharmacodynamics

Germany
Amorepacific Corporation

Completed

Cumulative Irritation Test of PAC-14028 in Healthy Volunteers

Healthy

Korea, Republic of
Active Biotech AB

Completed

A Single Dose Metabolism and Mass Balance Study of 14C-ABR-215050 in Healthy Subjects

Healthy

Sweden
Active Biotech AB

Active, not recruiting

A Study of Laquinimod Eye-drops in Healthy Participants

Eye Diseases

Austria
University Hospital, Ghent

Completed

What is the Influence of a Different Thread Pitch Design on Bone Remodelling Around Conical Southern Oral Implants?

Dental Implants

Belgium
Active Biotech AB

Completed

Efficacy Study of ABR-215050 to Treat Prostate Cancer

Prostate Cancer

United States, Canada, Sweden
Active Biotech AB

Completed

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer

France, Poland, Ukraine, United Kingdom, United States, China, Germany, Taiwan, Spain, Belgium, Colombia, Israel, Bulgaria, India, Panama, Romania, Netherlands, Greece, Sweden, Korea, Republic of, Australia, Canada, Chile, New Zealand, ... and more
Ipsen

Terminated

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer (TasQ003)

Prostatic Neoplasms, Castration-Resistant

China, Korea, Republic of, Taiwan
Facet Biotech

Completed

Research Study of Visilizumab for Treatment of Acute Graft Versus Host Disease

Graft vs Host Disease

United States
Kowa Company, Ltd.

Completed

A Clinical Pharmacology Study of K-877 Controlled Release Tablet

Dyslipidemias

Japan
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Sedation

China
Facet Biotech
PDL BioPharma, Inc.

Terminated

A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

Ulcerative Colitis

France, Belgium, United States, Israel, Australia, Germany, Netherlands, Austria, Canada, Czech Republic, Ukraine, Norway, Hungary, Slovakia
Shenzhen Fifth People's Hospital

Recruiting

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

CAR T-Cell Therapy

China
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Recruiting

A First-in-Human Study of QY211 Gel in Adult Subjects

Atopic Dermatitis

China
DR. MALA KHAN
Dhaka Medical College

Completed

Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo (VEP-COV)

COVID19

Bangladesh
Medtronic - MITG

Completed

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy

Anesthesia | Neuromuscular Blockade

United States
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Ipsen

Completed

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Metastatic Renal Cell Cancer | Advanced or Metastatic Hepatocellular Cancer | Advanced or Metastatic Ovarian Cancer | Advanced or Metastatic Gastric Carcinoma

Belgium, Canada, France, Spain, United Kingdom
University of Faisalabad

Not yet recruiting

Corneal Thickness Changes in Patient Undergoing Dry Eye Managment

Dry Eye Disease

Pakistan
Assiut University

Completed

Ultrasonographic Assessment of Lung Recruitment Maneuvers in Children Undergoing Lengthy Microsurgery Operations (RM)

Intraoperative Complications

Egypt
Quan Dong Nguyen
Global Ophthalmic Research Center (GORC)

Recruiting

Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study (LION)

Inflammation | Uveitis

United States
Shandong University

Unknown

Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine Staining

Image Quality of Early Esophageal Squamous Neoplasia | Endoscopists'Subjective Assessments

China
Ipsen

Terminated

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

Metastatic Castrate Resistant Prostate Cancer

France, Spain, Poland, Belgium, Germany, Italy, Denmark, Lithuania, United Kingdom, Czechia, Hungary
Patagonia Pharmaceuticals, LLC

Completed

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Congenital Ichthyosis

United States
Calm Water Therapeutics LLC
Andover Research Eye Institute

Completed

Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops

Dry Eye Disease

United States
Shandong University

Completed

Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining

Image Quality | Mucosal Irritation

China
Prove pharm

Recruiting

Indigotindisulfonate Sodium Injection, USP as an Aid in the Determination of Ureteral Patency

Ureter Injury

United States
Shaperon

Completed

A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

Atopic Dermatitis

Korea, Republic of
Kwang Dong Pharmaceutical co., ltd.

Completed

A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

Overactive Bladder

Korea, Republic of
M.D. Anderson Cancer Center
Active Biotech AB

Not yet recruiting

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-Essential Thrombocytosis Myelofibrosis

United States
Moberg Pharma AB

Completed

Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design (CIPT)

Erythema

United States

Search clinical trials for: Laquinimod 0.6

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations